O besity is an important risk factor for hypertension. 1 In normal physiology, the renin-angiotensin system (RAS) plays crucial roles in maintaining basal blood pressure, sodium and water homeostasis. Obesity is associated with an activated RAS, with elevations in systemic concentrations of the vasoactive peptide, angiotensin II (Ang II), and an increase in systolic blood pressure (SBP). [2][3][4][5][6][7] As might be expected given these findings, the use of angiotensin-converting enzyme inhibitors [8][9] [10] [11] [12] [13] or Ang II type 1 receptor antagonists 8, 14 to inhibit the RAS is an effective therapy for obesity-hypertension.
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Angiotensinogen (AGT) is the only known precursor to Ang II. Whole body deficiency of AGT markedly reduces plasma AGT and angiotensin peptide concentrations in mice. 15, 16 Although several cell types produce AGT, recent studies in mice with hepatocyte deficiency of AGT demonstrate robust reductions in plasma AGT concentrations. 17 The intrarenal RAS has been proposed as a self-contained RAS, where proximal tubule cells synthesize and secrete AGT into tubule fluid, 18 as well as take up AGT through a megalin-dependent mechanism. 19 In mice with hepatocyte AGT deficiency, renal AGT and Ang II were reduced, potentially related to reduced uptake of liver-derived AGT by megalin. 17 These results demonstrate an intrarenal RAS that is influenced by liver-derived AGT. An additional source of AGT is adipocytes, where adipocyte-specific deficiency of AGT reduces plasma AGT concentrations (by 15%-20%) and SBP (by 10-15 mm Hg) in normal mice. 20 Conversely, transgenic overexpression of AGT in adipocytes increases systemic AGT concentrations and SBP. [21] [22] [23] However, previous studies from our laboratory demonstrate that in mice with diet-induced obesity, adipocyte-specific deficiency of AGT did not prevent obesity-induced elevations in plasma AGT concentrations. 24 Notably, despite continued elevations in plasma AGT concentrations in adipocyte AGT-deficient obese mice, elevations in plasma Ang II concentrations and SBP were totally abolished. 24 These results suggest dissociations between the systemic and local RAS in the development of obesity-induced hypertension. Namely, obese mice with adipocyte AGT deficiency maintained high plasma AGT concentrations while experiencing reductions in plasma Ang II concentrations and Abstract-We recently demonstrated that adipocyte deficiency of angiotensinogen (AGT) ablated high-fat diet-induced elevations in plasma angiotensin II (Ang II) concentrations and obesity-hypertension in male mice. Hepatocytes are the predominant source of systemic AGT. Therefore, in this study, we defined the contribution of hepatocyte-derived AGT to obesity-induced elevations in plasma AGT concentrations and hypertension. Because adipocytes were recently demonstrated to be an important source of systemic Ang II concentrations in obesityinduced hypertension, 24 in this study we defined the contribution of hepatocyte-derived AGT to obesity-induced elevations in systemic AGT and Ang II concentrations. We also examined the role of hepatocyte-derived AGT in the regulation of adipose production of AGT and Ang II in the development of obesity-induced hypertension.
Methods

Animals
All procedures involving animals were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the institutional Animal Care and Use Committee at the University of Kentucky. Male C57BL/6 mice with loxP sites flanking exon 2 of the AGT gene 20, 24 (Agt fl/fl ; Figure 1A ) were bred to transgenic male mice expressing Cre recombinase under the control of the albumin promoter (Strain Name: B6.Cg-Tg(Alb-cre)21Mgn/J, Stock Number: 003574). 20 (Figure 2A ; P>0.05). Fat mass (expressed as % body weight) was increased significantly in HF-fed mice of each genotype compared with LF-fed controls, with no significant differences between genotypes ( Figure 2B ; P>0.05). HF feeding increased adipocyte size in tissue sections from mice of each genotype, with no significant differences between genotypes ( Figure S1A-S1C) . Similarly, livers from HF-fed mice exhibited significant Oil Red O staining as an index of lipid accumulation, with no overt differences between genotypes ( Figure S1D ). Total body water ( Figure S2 ) was increased significantly in HF-fed mice of each genotype compared with LF-fed controls. Moreover, total body water was decreased significantly in Agt Alb mice compared with Agt fl/fl controls in both the diet groups. The mass of liver, visceral, and brown adipose tissue were increased significantly in HF-fed mice of each genotype compared with LF-fed controls, with no significant differences between genotypes ( (Table 1) . Heart mass was increased significantly by HF feeding in both the genotypes; however, heart weights of HF-fed Agt Alb mice were significantly decreased compared with HF-fed Agt fl/fl controls. Glucose tolerance was significantly impaired in HF-fed mice 
Hepatocyte AGT Deficiency Upregulated the Intrarenal RAS
Recent studies demonstrated that liver AGT deficiency reduced kidney AGT concentrations, Ang II content, and promoted an abnormal kidney morphological phenotype. 17 Therefore, we quantified mRNA abundance of RAS components in kidneys from mice of each genotype and diet group. Renin and prorenin renin receptor mRNA abundance were increased significantly in kidneys from Agt Alb mice compared with Agt fl/fl controls, regardless of diet group (Figure S4A and S4B; P<0.05). However, mRNA abundance of AGT, angiotensin-converting enzyme, and Ang II type 1 receptor were not significantly altered by diet or genotype (Figure S4C-S4E ; P>0.05). Because megalin was reported to mediate uptake of liver-derived AGT by kidney, 17 we quantified megalin mRNA abundance in kidney, which was not significantly influenced by either diet or genotype ( Figure S4F ; P>0.05). We examined 
Ang II Stimulated Megalin mRNA Abundance and Decreased AGT Concentrations in Media of 3T3-L1 Adipocytes
We hypothesized that Ang II regulates megalin expression in adipocytes to influence local uptake of AGT in the feedback control of adipocyte Ang II synthesis. At low concentrations (10 nmol/L), Ang II increased significantly megalin mRNA abundance in 3T3-L1 adipocytes ( Figure 5A ; P<0.05).
However, at higher Ang II concentrations (100 nmol/L), there was no significant effect on megalin mRNA abundance. Concentrations of AGT in media from adipocytes incubated with Ang II (10 nmol/L) were decreased significantly compared with vehicle (0) ( Figure 5B ; P<0.05), but these effects were not apparent at higher Ang II concentrations.
Hepatocyte-Specific Deficiency of AGT Resulted in Marked Hypotension of HF-Fed Mice
There was no significant difference in SBP during the dark and light cycle in HF-fed compared with LF-fed Agt fl/fl mice ( Figure 6A ). There was a significant increase in SBP during the dark compared with light cycle of Agt fl/fl and Agt Alb mice in both the diet groups (P<0.05). In both LF-and HF-fed groups, hepatocyte AGT deficiency resulted in a significant reduction in SBP during the dark and light cycle compared with Agt fl/fl mice ( Figure 6; P<0.05 
Discussion
This study investigated the role of hepatocyte-derived AGT in blood pressure control during diet-induced obesity. As anticipated in LF-fed mice, hepatocyte deficiency of AGT reduced plasma AGT and Ang II concentrations, reducing SBP and diastolic blood pressure. Results demonstrate that obesity-induced elevations in plasma AGT concentrations are hepatocyte-derived because HF-fed mice with hepatocyte AGT deficiency exhibited marked reductions in plasma AGT concentrations. In addition, obese hepatocyte AGT-deficient mice exhibited pronounced reductions in systemic Ang II concentrations, and became hypotensive despite robust obesity. Surprisingly, as adipocytes express a high level of AGT that was demonstrated to contribute to the development of obesityhypertension, 24 AGT content and release from adipose tissue explants were reduced in mice with hepatocyte AGT deficiency. mRNA abundance of megalin, a transporter reported to mediate AGT uptake by kidney, 17 was stimulated by low concentrations of Ang II that decreased AGT concentrations in media. These results suggest that Ang II stimulates megalin to increase adipocyte AGT uptake. Taken together, results suggest that reductions in plasma Ang II concentrations of obese mice with hepatocyte AGT deficiency may contribute to reduced megalin-mediated uptake of hepatocyte-derived AGT by adipocytes. As a result, despite the presence of robust obesity, HF-fed mice with hepatocyte AGT deficiency become markedly hypotensive because of reductions in both adipose and systemic Ang II production. We demonstrated previously that adipocyte production of AGT accounted for ≈25% of circulating AGT concentrations in mice (2 or 12 months of age, male and female) fed standard mouse diet. 20 In this study, hepatocyte AGT deficiency in LF-fed mice reduced plasma AGT concentrations (by 63%), suggesting that the remainder of circulating AGT is derived from other sources, including adipocytes. 20 Although these data from hepatocyte versus adipocyte AGT-deficient knockout mouse models are consistent in their effects on plasma AGT concentrations, the magnitude of reductions in systemic AGT concentrations in hepatocyte AGT-deficient mice in this study are less than previously observed. 17 Previous results demonstrated that in male mice with diet-induced obesity, elevations in plasma AGT concentrations were not adipocyte-derived, as adipocyte AGT deficiency had no effect on obesity-induced increases in plasma AGT concentrations.
24
In this study, obesity-induced elevations in plasma AGT concentrations were totally abolished in male mice with hepatocyte AGT deficiency, supporting hepatocytes as the source of increased circulating AGT concentrations.
We demonstrated previously that adipocyte AGT is pivotal in obesity-induced increases in plasma Ang II concentrations and the development of obesity-hypertension. 24 Given these findings, 24 and that adipocytes express a relatively high level of AGT, 25 we were surprised by results demonstrating reductions in AGT content and release from adipose tissue explants of obese hepatocyte AGT-deficient mice. These results suggest that adipocyte AGT/Ang II production in obese mice is partially dependent on hepatocyte-derived AGT.
Previous studies demonstrated that liver-derived AGT influences the intrarenal RAS, with uptake and transcytosis of AGT via megalin in proximal tubule cells. 19 Our results extend a potential role for megalin in AGT uptake into adipocytes. A novel finding of this study is that Ang II stimulates megalin expression in adipocytes to potentially influence AGT uptake, a positive feedback loop that may contribute to local control of Ang II synthesis. In obese AGT hepatocyte-deficient mice with pronounced reductions in plasma Ang II concentrations, decreased expression of megalin may have contributed to reduced AGT uptake in the feedback control of adipocyte Ang II synthesis. We were also surprised to find that effects of hepatocyte AGT deficiency to reduce plasma AGT and Ang II concentrations and blood pressure were more pronounced in obese than lean mice. Indeed, obese mice with hepatocyte AGT deficiency became hypotensive, with SBPs averaging 85 mm Hg. A potential contributing factor to the pronounced effect of hepatocyte AGT deficiency to decrease plasma Ang II concentrations and blood pressure of obese mice is suppression of both systemic and adipose Ang II production. Because kidney is a primary site for production and function of Ang II, and has been implicated in the development of obesity-hypertension, 26 we quantified mRNA abundance of RAS components in kidneys from obese mice of each genotype. In agreement with previous findings, 17 we observed increased expression of renin and prorenin renin receptor in kidneys of obese hepatocyte AGT-deficient mice. However, unlike findings from hepatocyte AGT-deficient mice fed standard murine diet, 17 regulation of kidney RAS in obese mice with hepatocyte AGT deficiency was not associated with changes in renal pathology.
Perspectives
These results demonstrate interdependency of the systemic and adipose RAS in the regulation of blood pressure in mice with diet-induced obesity. Deficiency of AGT in hepatocytes abolished obesity-induced elevations in plasma AGT concentrations, and plummeted plasma Ang II concentrations. These effects were associated with hypotension despite obesity in hepatocyte AGT-deficient mice. Our findings suggest that Ang II may stimulate megalin to increase adipocyte uptake of AGT, exerting positive feedback control over local Ang II synthesis in obese mice. As a result, both adipose and systemic production of Ang II decreased in mice with hepatocyte AGT deficiency, resulting in hypotension. These results suggest that targeted inhibition of hepatocyte-derived AGT may serve as an effective therapeutic target for obesity-induced hypertension. However, given that obese mice with hepatocyte AGT deficiency were markedly hypotensive, therapies resulting in modest reductions in hepatocyte AGT expression may have greatest benefit in the therapy of obesity-induced hypertension.
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• Demonstration that hepatocyte AGT deficiency induces pronounced reductions in plasmas concentrations of AGT, angiotensin II (Ang II), and blood pressure despite the continued presence of obesity in high fat-fed mice.
• Demonstration that hepatocyte-derived AGT deficiency influences adipose AGT content and release.
• Demonstration that Ang II stimulates megalin expression in adipocytes, potentially contributing to feedback control of adipose Ang II synthesis.
What Is Relevant?
• This study demonstrates that the renin-angiotensin system is a primary contributor to the control of blood pressure in mice with diet-induced obesity.
• This study demonstrates interdependence of the systemic and adipose renin-angiotensin system in the control of blood pressure in mice with diet-induced obesity.
Summary
The effect of hepatocyte AGT deficiency to reduce blood pressure is profound in mice with diet-induced obesity, demonstrating a primary role for the renin-angiotensin system in the control of blood pressure in mice with diet-induced obesity. In obese mice, elevated plasma Ang II concentrations may promote megalin expression in adipocytes to increase AGT uptake and augment adipose production of Ang II. In mice with hepatocyte AGT deficiency, reductions in plasma Ang II concentrations may mitigate megalin-mediated AGT uptake and adipose AGT/Ang II synthesis.
